Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma.

J Immunother Cancer · 2020 · PMC7259841 · PMID 32467299

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Discussion The combination of SBRT and IL-2 showed a trend toward higher response and higher DCR compared with IL-2 monotherapy in patients with advanced melanoma yet no statistically significant differences in PFS or OS were observed.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.